All In Biotech

Drug Trial Radar · NCT05690711

A Trial of HRS8179 on Brain Swelling After Large Hemispheric Infarction

Efficacy and Safety of Intravenous HRS8179 on Brain Swelling After Large Hemispheric Infarction: a Randomised, Double-blind, Placebo-controlled Phase II Trial

Last checked: Nov 20, 2026Latest source record: Jan 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Apr 7, 2023

Primary completion

Dec 5, 2023

Study completion Feb 27, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to explore if HRS8179 could improve midline shift at 72 hours (or at time of decompressive craniectomy or comfort measures only, if earlier) in participants with large hemispheric infarction. The secondary objective is to explore if HRS8179 could improve acute neurologic status, functional outcomes, treatment requirements and safety.

Conditions

  • Brain Swelling, Large Hemispheric Infarction

Interventions

  • HRS8179Drug

    HRS8179 injection

  • PlaceboDrug

    physiological saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change between baseline and 72-78 hours in midline shift measured by MRI or CTTime frame: Baseline up to 72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.